StockGuru Blog: NextGen Bioscience (NXGB) – Potential Candidates and Acquisition Pipeline
Wednesday, April 9th, 2008 NexGen’s proprietary anti-cancer candidates include Prostaganin (targeting prostate cancer) and Tetanolic (targeting breast cancer) which have, in preliminary studies, shown to be able to target cancer cells without affecting normal tissue and therefore have potential to be developed into blockbuster drugs. These patented product candidates hold the potential to treat cancer in a way that is effective and safe for the patient. An exciting acquisition pipeline, including in oncology therapeutics, cancer vaccines and anti-bacterial drugs, ensures that the Company is constantly positioned as a leader in the forefront of developments in treating cancer and infectious disease.…